Cinta de Diego-Cabanes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cinta de Diego-Cabanes has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Eva M. Satué-Gracia
Institut Català de la Salut, Tarragona, Spain
3 shared publications- Eva María Satué Gracia
Institut Català de la Salut. Camp de Tarragona Primary Care Unit. Primary Care Research Support Unit Reus-Tarragona., Spain
3 shared publications Alba Gómez González
2 shared publications- Alba Hernández-Pinilla
Servicio de Atención Primaria Camp de Tarragona, Institut Català de la Salut, 43761 Tarragona, Spain
2 shared publications Angel Vila-Córcoles
Institut Català de la Salut. Primary Health Care Service Camp de Tarragona, Institut Català de la Salut, Tarragona, Spain
2 shared publications- Anna Diaz-Vilarasau
Department of Primary Care Camp de Tarragona, Institut Català de la Salut, 43005 Tarragona, Spain
2 shared publications
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA1659
Multimorbidity and increasing risk of pneumococcal pneumonia: a population‑based study in adults aged ≥50 years in Catalonia.
Background: Pneumococcal pneumonia (PP) is a major cause of morbidity and mortality in older adults and individuals with underlying conditions. Evidence suggests that cumulative comorbidity burden may be a key determinant of vulnerability beyond traditional risk classifications. Aim: To quantify the burden and identify risk factors for hospitalised PP among adults aged ≥50 years in Catalonia, with a specific focus on the impact of multimorbidity. Methods: A population‑based cohort study including 2,234,003 adults aged ≥50 years living in Catalonia was retrospectively followed throughout 2019. Baseline demographics and underlying conditions were obtained from primary care electronic health records and linked to hospital discharge data. PP hospitalisations were identified using ICD‑10 code J13. Cox regression models estimated the risk of PP associated with individual comorbidities and with increasing comorbidity burden. Results: A total of 2,319 hospitalised PP cases were identified, corresponding to an incidence rate (IR) of 105.7 per 100,000 person‑years. IRs rose sharply with age, reaching 288.8 per 100,000 in individuals ≥80 years. The highest IRs were observed in those with chronic respiratory disease, severe renal disease, HIV infection and asplenia. A strong gradient was seen across comorbidity burden: IRs increased from 39.5 per 100,000 in individuals without comorbidities to 1,113.6 in those with ≥5. Adjusted hazard ratios rose progressively from 2.09 for one comorbidity to 16.71 for five or more. Conclusion: PP imposes a substantial burden in older adults, strongly influenced by cumulative comorbidity burden. These findings support a risk‑continuum approach and highlight the value of incorporating multimorbidity into pneumococcal vaccination risk stratification.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA1659
Multimorbidity and increasing risk of pneumococcal pneumonia: a population‑based study in adults aged ≥50 years in Catalonia.
Background: Pneumococcal pneumonia (PP) is a major cause of morbidity and mortality in older adults and individuals with underlying conditions. Evidence suggests that cumulative comorbidity burden may be a key determinant of vulnerability beyond traditional risk classifications. Aim: To quantify the burden and identify risk factors for hospitalised PP among adults aged ≥50 years in Catalonia, with a specific focus on the impact of multimorbidity. Methods: A population‑based cohort study including 2,234,003 adults aged ≥50 years living in Catalonia was retrospectively followed throughout 2019. Baseline demographics and underlying conditions were obtained from primary care electronic health records and linked to hospital discharge data. PP hospitalisations were identified using ICD‑10 code J13. Cox regression models estimated the risk of PP associated with individual comorbidities and with increasing comorbidity burden. Results: A total of 2,319 hospitalised PP cases were identified, corresponding to an incidence rate (IR) of 105.7 per 100,000 person‑years. IRs rose sharply with age, reaching 288.8 per 100,000 in individuals ≥80 years. The highest IRs were observed in those with chronic respiratory disease, severe renal disease, HIV infection and asplenia. A strong gradient was seen across comorbidity burden: IRs increased from 39.5 per 100,000 in individuals without comorbidities to 1,113.6 in those with ≥5. Adjusted hazard ratios rose progressively from 2.09 for one comorbidity to 16.71 for five or more. Conclusion: PP imposes a substantial burden in older adults, strongly influenced by cumulative comorbidity burden. These findings support a risk‑continuum approach and highlight the value of incorporating multimorbidity into pneumococcal vaccination risk stratification.
- Open Access
- 21 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-12
Real world effectiveness of antipneumococcal vaccination against pneumonia in adults: a population-based cohort study, Catalonia, 2019
Despite recognised benefits against vaccine-type pneumococcal infections, limited and inconsistent evidence exists on the effectiveness of pneumococcal vaccination in preventing pneumococcal and all-cause pneumonia in adults. This study investigated clinical effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPsV23) against hospitalised pneumococcal pneumonia (PP) and/or all-cause pneumonia (ACP) among middle-aged and older adults before COVID-19 pandemic started. Population-based cohort study involving 2,234,003 persons ≥ 50 years old in Catalonia, Spain, followed between 01/01/2019-31/12/2019. An Institutional Research database (SIDIAP-DB) was used to establish baseline characteristics of cohort members (demographics, underlying-risk conditions, vaccinations’ history) and hospitalisations from PP/ACP were captured by hospital discharge codes (ICD10: J12-J18) in 68 referral Catalonian hospitals. Cox regression was used to evaluate the association between receipt of PCV13/PPsV23 and risk of PP/ACP. Cohort members were followed for 2,194,200 person-years (23,494 PCV13-vaccinated and 783,465 PPsV23-vaccinated), observing 2319 hospitalised PP cases (110 in PCV13-vaccinated, 1558 in PPsV23-vaccinated) and 12,848 hospitalised-ACP cases (542 in PCV13-vaccinated, 9097 in PPsV23-vaccinated). Receipt PCV13 was associated with a greater risk of PP (multivariable-hazard ratio [MHR]: 1.83; 95%CI: 1.49–2.24) and ACP (MHR: 1.55; 95%CI: 1.42–1.70). Receipt PPsV23was also associated with increased risk of PP (MHR: 1.21; 95%CI: 1.10–1.36) and ACP (MHR: 1.24; 95%CI: 1.18–1.31) in the overall study cohort. Vaccination did not significantly alter the risk of death from PP/ACP. In sensitive analyses restricted to elderly (≥ 65 years old) and at-risk persons (immunocompromised, chronic respiratory/cardiac disease), PCV13 and/or PPsV23 did not emerge effective either. This study did not find evidence of the clinical effectiveness of PPsV23/PCV13 vaccination in preventing the outcomes measured at population-based level. At present, new extended-valency, PCVs (PCV15/PCV20/PCV21) have been marketed for using in adults and, logically, vaccines’ effectiveness must be re-evaluated in the coming years.
- 21 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-12
Open AccessReal world effectiveness of antipneumococcal vaccination against pneumonia in adults: a population-based cohort study, Catalonia, 2019
Despite recognised benefits against vaccine-type pneumococcal infections, limited and inconsistent evidence exists on the effectiveness of pneumococcal vaccination in preventing pneumococcal and all-cause pneumonia in adults. This study investigated clinical effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPsV23) against hospitalised pneumococcal pneumonia (PP) and/or all-cause pneumonia (ACP) among middle-aged and older adults before COVID-19 pandemic started. Population-based cohort study involving 2,234,003 persons ≥ 50 years old in Catalonia, Spain, followed between 01/01/2019-31/12/2019. An Institutional Research database (SIDIAP-DB) was used to establish baseline characteristics of cohort members (demographics, underlying-risk conditions, vaccinations’ history) and hospitalisations from PP/ACP were captured by hospital discharge codes (ICD10: J12-J18) in 68 referral Catalonian hospitals. Cox regression was used to evaluate the association between receipt of PCV13/PPsV23 and risk of PP/ACP. Cohort members were followed for 2,194,200 person-years (23,494 PCV13-vaccinated and 783,465 PPsV23-vaccinated), observing 2319 hospitalised PP cases (110 in PCV13-vaccinated, 1558 in PPsV23-vaccinated) and 12,848 hospitalised-ACP cases (542 in PCV13-vaccinated, 9097 in PPsV23-vaccinated). Receipt PCV13 was associated with a greater risk of PP (multivariable-hazard ratio [MHR]: 1.83; 95%CI: 1.49–2.24) and ACP (MHR: 1.55; 95%CI: 1.42–1.70). Receipt PPsV23was also associated with increased risk of PP (MHR: 1.21; 95%CI: 1.10–1.36) and ACP (MHR: 1.24; 95%CI: 1.18–1.31) in the overall study cohort. Vaccination did not significantly alter the risk of death from PP/ACP. In sensitive analyses restricted to elderly (≥ 65 years old) and at-risk persons (immunocompromised, chronic respiratory/cardiac disease), PCV13 and/or PPsV23 did not emerge effective either. This study did not find evidence of the clinical effectiveness of PPsV23/PCV13 vaccination in preventing the outcomes measured at population-based level. At present, new extended-valency, PCVs (PCV15/PCV20/PCV21) have been marketed for using in adults and, logically, vaccines’ effectiveness must be re-evaluated in the coming years.
- Open Access
- 7 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 119
Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)
Background/Objectives: In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3–5 individuals after the age of 55 years and a 34% rise in AF-related strokes. The PREFATE project investigates evidence gaps in the early detection of atrial fibrillation in high-risk populations within primary care. This study aims to estimate the prevalence of device-detected atrial fibrillation (DDAF) and assess the feasibility and impact of systematic screening in routine primary care. Methods: The prospective cohort study (NCT 05772806) included 149 patients aged 65–85 years, identified as high-risk for AF. Participants underwent 14 days of cardiac rhythm monitoring using the Fibricheck® app (CE certificate number BE16/819942412), alongside evaluations with standard ECG and transthoracic echocardiography. The primary endpoint was a new AF diagnosis confirmed by ECG or Holter monitoring. Statistical analyses examined relationships between AF and clinical, echocardiographic, and biomarker variables. Results: A total of 18 cases (12.08%) were identified as positive for possible DDAF using FibriCheck® and 13 new cases of AF were diagnosed during follow-up, with a 71.4-fold higher probability of confirming AF in FibriCheck®-positive individuals than in FibriCheck®-negative individuals, resulting in a post-test odds of 87.7%. Significant echocardiographic markers of AF included reduced left atrial strain (<26%) and left atrial ejection fraction (<50%). MVP ECG risk scores ≥ 4 strongly predicted new AF diagnoses. However, inconsistencies in monitoring outcomes and limitations in current guidelines, particularly regarding AF burden, were observed. Conclusions: The study underscores the feasibility and utility of AF screening in primary care but identifies critical gaps in diagnostic criteria, anticoagulation thresholds, and guideline recommendations.
- 7 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 119
Open AccessEvidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)
Background/Objectives: In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3–5 individuals after the age of 55 years and a 34% rise in AF-related strokes. The PREFATE project investigates evidence gaps in the early detection of atrial fibrillation in high-risk populations within primary care. This study aims to estimate the prevalence of device-detected atrial fibrillation (DDAF) and assess the feasibility and impact of systematic screening in routine primary care. Methods: The prospective cohort study (NCT 05772806) included 149 patients aged 65–85 years, identified as high-risk for AF. Participants underwent 14 days of cardiac rhythm monitoring using the Fibricheck® app (CE certificate number BE16/819942412), alongside evaluations with standard ECG and transthoracic echocardiography. The primary endpoint was a new AF diagnosis confirmed by ECG or Holter monitoring. Statistical analyses examined relationships between AF and clinical, echocardiographic, and biomarker variables. Results: A total of 18 cases (12.08%) were identified as positive for possible DDAF using FibriCheck® and 13 new cases of AF were diagnosed during follow-up, with a 71.4-fold higher probability of confirming AF in FibriCheck®-positive individuals than in FibriCheck®-negative individuals, resulting in a post-test odds of 87.7%. Significant echocardiographic markers of AF included reduced left atrial strain (<26%) and left atrial ejection fraction (<50%). MVP ECG risk scores ≥ 4 strongly predicted new AF diagnoses. However, inconsistencies in monitoring outcomes and limitations in current guidelines, particularly regarding AF burden, were observed. Conclusions: The study underscores the feasibility and utility of AF screening in primary care but identifies critical gaps in diagnostic criteria, anticoagulation thresholds, and guideline recommendations.
- Open Access
- 17 December 2024
- Published by MDPI AG in Preprints.org
Evidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)
Background/Objectives: In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3-5 individuals after the age of 55 years and a 34% rise in AF-related strokes. The PREFATE project investigates evidence gaps in the early detection of atrial fibrillation in high-risk populations within primary care. This study aims to estimate the prevalence of device-detected atrial fibrillation (DDAF) and assess the feasibility and impact of systematic screening in routine primary care. Methods: prospective cohort study (NCT 05772806) included 149 patients aged 65–85 years, identified as high-risk for AF. Participants underwent 14 days of cardiac rhythm monitoring using the Fibricheck® app, alongside evaluations with standard ECG and transthoracic echocardiography. The primary endpoint was a new AF diagnosis confirmed by ECG or Holter monitoring. Statistical analyses examined relationships between AF and clinical, echocardiographic, and biomarker variables. Results: A total of 18 cases (12.08%) were identified as positive for possible DDAF using FibriCheck® and 13 new cases of AF were diagnosed during follow-up, with a 71.4-fold higher probability of confirming AF in FibriCheck®-positive individuals than in FibriCheck®-negative individuals, resulting in a post-test odds of 87.7%. Significant echocardiographic markers of AF included reduced left atrial strain (<26%) and left atrial ejection fraction (<50%). MVP ECG risk scores ≥4 strongly predicted new AF diagnoses. However, inconsistencies in monitoring outcomes and limitations in current guidelines, particularly regarding AF burden, were observed. Conclusions: The study underscores the feasibility and utility of AF screening in primary care but identifies critical gaps in diagnostic criteria, anticoagulation thresholds, and guideline recommendations.
- 17 December 2024
- Published by MDPI AG in Preprints.org
Open AccessEvidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)
Background/Objectives: In Europe, the prevalence of AF is expected to increase 2.5-fold over the next 50 years with a lifetime risk of 1 in 3-5 individuals after the age of 55 years and a 34% rise in AF-related strokes. The PREFATE project investigates evidence gaps in the early detection of atrial fibrillation in high-risk populations within primary care. This study aims to estimate the prevalence of device-detected atrial fibrillation (DDAF) and assess the feasibility and impact of systematic screening in routine primary care. Methods: prospective cohort study (NCT 05772806) included 149 patients aged 65–85 years, identified as high-risk for AF. Participants underwent 14 days of cardiac rhythm monitoring using the Fibricheck® app, alongside evaluations with standard ECG and transthoracic echocardiography. The primary endpoint was a new AF diagnosis confirmed by ECG or Holter monitoring. Statistical analyses examined relationships between AF and clinical, echocardiographic, and biomarker variables. Results: A total of 18 cases (12.08%) were identified as positive for possible DDAF using FibriCheck® and 13 new cases of AF were diagnosed during follow-up, with a 71.4-fold higher probability of confirming AF in FibriCheck®-positive individuals than in FibriCheck®-negative individuals, resulting in a post-test odds of 87.7%. Significant echocardiographic markers of AF included reduced left atrial strain (<26%) and left atrial ejection fraction (<50%). MVP ECG risk scores ≥4 strongly predicted new AF diagnoses. However, inconsistencies in monitoring outcomes and limitations in current guidelines, particularly regarding AF burden, were observed. Conclusions: The study underscores the feasibility and utility of AF screening in primary care but identifies critical gaps in diagnostic criteria, anticoagulation thresholds, and guideline recommendations.
- Open Access
- 8 June 2023
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-11
Incidence and risk factors of pneumococcal pneumonia in adults: a population-based study
Background: Infection caused by Streptococcus pneumoniae, mainly invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP), are a major public health problem worldwide. This study investigated population-based incidence and risk of PP among Catalonian persons ≥ 50 years-old with and without specific underlying conditions/comorbidities, examining the influence of single and multi-comorbidities in the risk of suffering PP. Methods: Population-based cohort study involving 2,059,645 persons ≥ 50 years-old in Catalonia, Spain, who were retrospectively followed between 01/01/2017-31/12/2018. The Catalonian information system for development of research in primary care (SIDIAP) was used to establish baseline characteristics of the cohort (comorbidities/underlying conditions), and PP cases were collected from discharge codes (ICD-10: J13) of the 68 referral Catalonian hospitals. Results: Global incidence rate (IR) was 90.7 PP cases per 100,000 person-years, with a 7.6% (272/3592) case-fatality rate (CFR). Maximum IRs emerged among persons with history of previous IPD or all-cause pneumonia, followed by haematological neoplasia (475.0), HIV-infection (423.7), renal disease (384.9), chronic respiratory disease (314.7), liver disease (232.5), heart disease (221.4), alcoholism (204.8), solid cancer (186.2) and diabetes (159.6). IRs were 42.1, 89.9, 201.1, 350.9, 594.3 and 761.2 in persons with 0, 1, 2, 3, 4 and ≥ 5 comorbidities, respectively. In multivariable analyses, HIV-infection (hazard ratio [HR]: 5.16; 95% CI: 3.57–7.46), prior all-cause pneumonia (HR: 3.96; 95% CI: 3.45–4.55), haematological neoplasia (HR: 2.71; 95% CI: 2.06–3.57), chronic respiratory disease (HR: 2.66; 95% CI: 2.47–2.86) and prior IPD (HR: 2.56; 95% CI: 2.03–3.24) were major predictors for PP. Conclusion: Apart of increasing age and immunocompromising conditions (classically recognised as high-risk conditions), history of prior IPD/pneumonia, presence of chronic pulmonary/respiratory disease and/or co-existing multi-comorbidity (i.e., two or more underlying conditions) are major risk factors for PP in adults, with an excess risk near to immunocompromised subjects. Redefining risk categories for PP, including all the above-mentioned conditions into the high-risk category, could be necessary to improve prevention strategies in middle-aged and older adults.
- 8 June 2023
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-11
Open AccessIncidence and risk factors of pneumococcal pneumonia in adults: a population-based study
Background: Infection caused by Streptococcus pneumoniae, mainly invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP), are a major public health problem worldwide. This study investigated population-based incidence and risk of PP among Catalonian persons ≥ 50 years-old with and without specific underlying conditions/comorbidities, examining the influence of single and multi-comorbidities in the risk of suffering PP. Methods: Population-based cohort study involving 2,059,645 persons ≥ 50 years-old in Catalonia, Spain, who were retrospectively followed between 01/01/2017-31/12/2018. The Catalonian information system for development of research in primary care (SIDIAP) was used to establish baseline characteristics of the cohort (comorbidities/underlying conditions), and PP cases were collected from discharge codes (ICD-10: J13) of the 68 referral Catalonian hospitals. Results: Global incidence rate (IR) was 90.7 PP cases per 100,000 person-years, with a 7.6% (272/3592) case-fatality rate (CFR). Maximum IRs emerged among persons with history of previous IPD or all-cause pneumonia, followed by haematological neoplasia (475.0), HIV-infection (423.7), renal disease (384.9), chronic respiratory disease (314.7), liver disease (232.5), heart disease (221.4), alcoholism (204.8), solid cancer (186.2) and diabetes (159.6). IRs were 42.1, 89.9, 201.1, 350.9, 594.3 and 761.2 in persons with 0, 1, 2, 3, 4 and ≥ 5 comorbidities, respectively. In multivariable analyses, HIV-infection (hazard ratio [HR]: 5.16; 95% CI: 3.57–7.46), prior all-cause pneumonia (HR: 3.96; 95% CI: 3.45–4.55), haematological neoplasia (HR: 2.71; 95% CI: 2.06–3.57), chronic respiratory disease (HR: 2.66; 95% CI: 2.47–2.86) and prior IPD (HR: 2.56; 95% CI: 2.03–3.24) were major predictors for PP. Conclusion: Apart of increasing age and immunocompromising conditions (classically recognised as high-risk conditions), history of prior IPD/pneumonia, presence of chronic pulmonary/respiratory disease and/or co-existing multi-comorbidity (i.e., two or more underlying conditions) are major risk factors for PP in adults, with an excess risk near to immunocompromised subjects. Redefining risk categories for PP, including all the above-mentioned conditions into the high-risk category, could be necessary to improve prevention strategies in middle-aged and older adults.
- 1 January 2023
- Published by e-Medfarma 2020, S.L. in Medicina General y de Familia
- Vol. 12 (5) , 197-204
Validez predictiva de los signos y síntomas de la COVID-19
Estudiar la posible validez predictiva diagnóstica de los síntomas de presentación de COVID-19, así como la sensibilidad (S)
- 1 January 2023
- Published by e-Medfarma 2020, S.L. in Medicina General y de Familia
- Vol. 12 (5) , 197-204
Validez predictiva de los signos y síntomas de la COVID-19
Estudiar la posible validez predictiva diagnóstica de los síntomas de presentación de COVID-19, así como la sensibilidad (S)
- 1 January 2023
- Published by e-Medfarma 2020, S.L. in Medicina General y de Familia
- Vol. 12 (5) , 197-204
Validez predictiva de los signos y síntomas de la COVID-19
Estudiar la posible validez predictiva diagnóstica de los síntomas de presentación de COVID-19, así como la sensibilidad (S)
- 1 January 2023
- Published by e-Medfarma 2020, S.L. in Medicina General y de Familia
- Vol. 12 (5) , 197-204
Validez predictiva de los signos y síntomas de la COVID-19
Estudiar la posible validez predictiva diagnóstica de los síntomas de presentación de COVID-19, así como la sensibilidad (S)
- Open Access
- 27 April 2018
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 1-10
Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study
Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia among middle-aged and older adults. Population-based cohort study involving 2,025,730 individuals ≥50 years in Catalonia, Spain, who were prospectively followed from 01/01/2015 to 31/12/2015. Primary outcomes were hospitalisation for pneumococcal or all-cause pneumonia and death from any cause. Cox regression models were used to evaluate the association between PCV13 vaccination and the risk of each outcome, adjusting for age, sex and major comorbidities/underlying risk conditions. Cohort members were observed for a total of 1,990,701 person-years, of which 6912 person-years were PCV13 vaccinated. Overall, crude incidence rates (per 100,000 person-years) were 82.8 (95% confidence interval [CI]: 77.7–88.1) for pneumococcal pneumonia, 637.9 (95% CI: 599.0–678.7) for all-cause pneumonia and 2367.2 (95% CI: 2222.8–2518.7) for all-cause death. After multivariable adjustments we found that the PCV13 vaccination did not alter significantly the risk of pneumococcal pneumonia (multivariable-adjusted hazard ratio [mHR]: 1.17; 95% CI: 0.75–1.83; p = 0.493) and all-cause death (mHR: 1.07; 95% CI: 0.97–1.18; p = 0.190), although it remained significantly associated with an increased risk of all-cause pneumonia (mHR: 1.69; 95% CI: 1.48–1.94; p < 0.001). In stratified analyses focused on middle-aged or elderly persons and immunocompromised or immunocompetent subjects, PCV13 vaccination did not appear effective either. Our data does not support clinical benefits of PCV13 vaccination against pneumonia among adults in Catalonia. It must be closely monitored in future studies involving more vaccinated person-time at-observation.
- 27 April 2018
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 1-10
Open AccessEvaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study
Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia among middle-aged and older adults. Population-based cohort study involving 2,025,730 individuals ≥50 years in Catalonia, Spain, who were prospectively followed from 01/01/2015 to 31/12/2015. Primary outcomes were hospitalisation for pneumococcal or all-cause pneumonia and death from any cause. Cox regression models were used to evaluate the association between PCV13 vaccination and the risk of each outcome, adjusting for age, sex and major comorbidities/underlying risk conditions. Cohort members were observed for a total of 1,990,701 person-years, of which 6912 person-years were PCV13 vaccinated. Overall, crude incidence rates (per 100,000 person-years) were 82.8 (95% confidence interval [CI]: 77.7–88.1) for pneumococcal pneumonia, 637.9 (95% CI: 599.0–678.7) for all-cause pneumonia and 2367.2 (95% CI: 2222.8–2518.7) for all-cause death. After multivariable adjustments we found that the PCV13 vaccination did not alter significantly the risk of pneumococcal pneumonia (multivariable-adjusted hazard ratio [mHR]: 1.17; 95% CI: 0.75–1.83; p = 0.493) and all-cause death (mHR: 1.07; 95% CI: 0.97–1.18; p = 0.190), although it remained significantly associated with an increased risk of all-cause pneumonia (mHR: 1.69; 95% CI: 1.48–1.94; p < 0.001). In stratified analyses focused on middle-aged or elderly persons and immunocompromised or immunocompetent subjects, PCV13 vaccination did not appear effective either. Our data does not support clinical benefits of PCV13 vaccination against pneumonia among adults in Catalonia. It must be closely monitored in future studies involving more vaccinated person-time at-observation.